Advertisement
Organisation › Details
Glycotope (Group)
Glycotope (www.glycotope.com), founded in 2001 in Berlin, focuses on the development of innovative immune-oncological products for the treatment of various cancer types using their GlycoBody™ and GlycoExpress™ technologies. Glycotope´s GEX™ platform allows glyco-optimization of a variety of fully human glycosylated biopharmaceuticals such as coagulation factors, cytokines, glycoprotein hormones, antibodies, and other protein based biopharmaceuticals by using a toolbox of glyco-engineered proprietary human cell lines that allow for optimization of a whole series of different determining sugars. In addition, the GEX™ platform offers high yield production with unmet quality and reproducibility. Glycotope’s entire human blood coagulation business was recently partnered with Octapharma in an exclusive strategic deal in October 2015. *
Start | 2001-01-01 established | |
Industry | GlycoExpress™ cellular expression system (GEX™ technology) | |
Industry 2 | glycomics | |
Person | Kollenberg, Henner (Glycotope 201403– Managing Director (CFO) + Eckert Life Science Acclerator before Qonsult Group) | |
Person 2 | Bracht, Franzpeter (Celonic 201711– COO before Glycotope + Aplagen + Ernst & Young + Kienbaum) | |
Region | Berlin | |
Country | Germany | |
Street | 10 Robert-Rössle-Str. Campus Berlin-Buch | |
City | 13125 Berlin | |
Tel | +49-30-9489-2604 | |
Address record changed: 2023-07-23 | ||
Basic data | Employees | D: 101 to 500 (2016-01-07) |
* Document for »About Section«: | ||
Record changed: 2023-12-30 |
Advertisement
More documents for Glycotope (Group)
- [1] Glycotope GmbH. (2/1/22). "Press Release: Glycotope to Spin-out Its Service Business to the Newly Formed FyoniBio GmbH". Berlin....
- [2] Glycotope GmbH. (7/27/21). "Press Release: Byondis and Glycotope Enter Platform Access Agreement for Discovery and Development of Antibodies Against Novel GlycoTargets". Nijmegen & Berlin....
- [3] Glycotope GmbH. (9/21/20). "Press Release: DCprime and Glycotope Sign Licensing Agreement to Advance Program Combining Cancer Vaccination and Therapeutic Antibody Platforms". Leiden & Berlin....
- [4] Valo Therapeutics Ltd.. (8/3/20). "Press Release: Valo Therapeutics Appoints Industry Veteran Paul G Higham as CEO". Oxford & Helsinki....
- [5] Glycotope GmbH. (7/18/18). "Press Release: DCPrime and Glycotope Announce Licensing Agreement and Collaboration". Leiden & Berlin....
- [6] Glycotope GmbH. (10/30/17). "Press Release: Daiichi Sankyo and Glycotope Announce Option Agreement for Antibody Drug Conjugate Strategic Collaboration and Licensing". Tokyo, Basking Ridge, NJ & Berlin....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top